江苏省成人2型糖尿病药物治疗路径专家共识(2025年版)OA

Type 2 diabetes mellitus is a chronic metabolic disease characterized by a high prevalence rate,a significant disease burden,and the need for long-term standardized management.The latest national epidemiological data reveal that in Jiang-su Province in 2023,the age-standardized prevalence of diabetes has reached 16.35％,ranking among the highest among provin-cial-level administrative regions in China and highlighting the severe challenges of diabetes prevention and control in Jiangsu Province.Effective pharmacological treatment is crucial for controlling blood glucose levels,delaying complications,and improving patients'quality of life.Based on the latest domestic and international authoritative guidelines for the diagnosis and treatment of a-dult type 2 diabetes,this consensus focuses on the selection of pharmacological treatment strategies at different stages of disease progression.It refines the medication regimens recommended in the guidelines in the form of a structured pathway,clarifies the therapeutic positioning,target populations,dosage ranges,and administration regimens of various classes of hypoglycemic drugs,while emphasizing the standardization and timeliness of pharmacological treatment.The aim is to establish a standardized pharma-cological treatment pathway,bridge the gap between clinical guidelines and practice,provide clinicians with pathway-based treat-ment strategies,and offer solutions for rational drug use in clinical settings.